Bavarian Nordic (OTCMKTS:BVNRY – Get Free Report) issued its quarterly earnings results on Friday. The company reported $0.46 earnings per share for the quarter, Zacks reports. Bavarian Nordic had a net margin of 19.74% and a return on equity of 9.32%.
Bavarian Nordic Stock Up 9.2%
BVNRY stock opened at $10.88 on Friday. Bavarian Nordic has a twelve month low of $8.67 and a twelve month high of $13.00. The company has a market cap of $2.59 billion, a PE ratio of 14.31 and a beta of 1.20. The business’s 50-day simple moving average is $9.30 and its 200 day simple moving average is $9.69.
About Bavarian Nordic
Bavarian Nordic is a fully integrated biotechnology company specializing in the development, manufacture and commercialization of vaccines and immunotherapies. Founded in 1994 and headquartered in Martinsried, Germany, the company combines internal research capabilities with in-house manufacturing to address serious infectious diseases and cancer indications. Bavarian Nordic’s operations encompass preclinical research, clinical development and commercial supply, with a strategic focus on leveraging its proprietary viral vector platforms.
The company’s commercial portfolio includes approved prophylactic vaccines such as Jynneos™ (marketed as Imvamune®/Imvanex®) for the prevention of smallpox and monkeypox in the United States, European Union and Canada; Rabipur® for rabies prevention; and Encepur® against tick-borne encephalitis.
Featured Stories
- Five stocks we like better than Bavarian Nordic
- MarketBeat Week in Review – 08/17 – 08/21
- Blueprint for a Boom: SEC Clears the Crypto Runway
- Ross Stores Just Flipped the Off-Price Retail Story After TJX’s Marmaxx Miss
- Advance Auto Parts Plunged, But Its Turnaround Is Still Working
Receive News & Ratings for Bavarian Nordic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bavarian Nordic and related companies with MarketBeat.com's FREE daily email newsletter.
